South Korea’s FTC Looking Into Sanofi Aventis and Novartis For Price Inflation – Industry Insiders
This article was originally published in PharmAsia News
SEOUL - As South Korea's government agencies move to tighten surveillance on illegal and unfair deals in the pharma industry, the Fair Trade Commission is now looking into several companies including Sanofi-Aventis and Novartis to investigate inflated prices on their products which are considerably more expensive in South Korea than in other countries such as the U.S. and UK, according to industry insiders
You may also be interested in...
SEOUL - One month after denying it would seek tightened legal restrictions and punishment for doctors who accept kickbacks from pharmaceutical companies, South Korea's Ministry for Health, Welfare and Family Affairs said April 6 it now supports a bill submitted to the National Assembly to suspend licenses of doctors who participate in the practice
SEOUL - South Korea's trade watchdog, the Fair Trade Commission, has imposed fines collectively totaling KRW 20.48 billion ($14.8 million) on seven pharmaceutical companies - including five multinationals - on charges of unfair provision of rebates and other improper benefits to doctors and hospitals
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).